SARS‐CoV‐2 vaccine clinical efficacy in SOT: What we know and our current gaps
Open Access
- 25 February 2022
- journal article
- editorial
- Published by Wiley in Transplant Infectious Disease
- Vol. 24 (2) , e13809
Abstract
No abstract availableKeywords
Funding Information
- Cystic Fibrosis Foundation (ASLAM20A0‐I to SA)
This publication has 28 references indexed in Scilit:
- Safety and Immunogenicity of Anti–SARS-CoV-2 Messenger RNA Vaccines in Recipients of Solid Organ TransplantsAnnals of Internal Medicine, 2021
- Occurrence of severe COVID-19 in vaccinated transplant patientsKidney International, 2021
- Immunogenicity of BNT162b2 mRNA COVID-19 vaccine and SARS-CoV-2 infection in lung transplant recipientsThe Journal of Heart and Lung Transplantation, 2021
- Clinically Significant COVID-19 Following SARS-CoV-2 Vaccination in Kidney Transplant RecipientsAmerican Journal of Kidney Diseases, 2021
- Antibody response to SARS-CoV-2 mRNA vaccine among kidney transplant recipients: a prospective cohort studyClinical Microbiology and Infection, 2021
- Early experience with SARs‐CoV‐2 mRNA vaccine breakthrough among kidney transplant recipientsTransplant Infectious Disease, 2021
- Severe consequences of COVID-19 infection among vaccinated kidney transplant recipientsAmerican Journal of Transplantation, 2021
- Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant RecipientsJAMA, 2021
- Reduced humoral response to mRNA SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virusAmerican Journal of Transplantation, 2021
- Poor Anti-SARS-CoV-2 Humoral and T-cell Responses After 2 Injections of mRNA Vaccine in Kidney Transplant Recipients Treated With BelataceptTransplantation, 2021